NeuroThera Labs Inc. (TSXV: NTLX) announced today that it has successfully completed internal validation of a proprietary quantum sampling workflow developed for its clinical trials data analysis platform. The validation was conducted using an S&P 500 company's hybrid quantum-classical computing platform, demonstrating the ability to represent and analyze continuous probability distributions within a quantum computing framework.
The validated workflow is a key component of the platform's computational architecture, which is being advanced through CliniQuantum, a quantum-focused technology initiative in which NeuroThera holds a 54.01% stake. The platform aims to address complex analytical challenges involving large-scale clinical and biomedical datasets.
Many real-world challenges in healthcare, life sciences, and drug development are naturally represented as continuous probability distributions. NeuroThera's proprietary methodology converts these continuous datasets into quantum-operable energy landscape representations, enabling the application of Quantum Markov Chain Monte Carlo (QMCMC) techniques while preserving the statistical characteristics of the original data.
By using the platform, quantum dynamics generate proposed samples while a classical acceptance mechanism preserves the target probability distribution. This hybrid quantum-classical architecture allows continuous datasets to be explored through quantum-generated proposals while maintaining established statistical guarantees.
The Company believes that efficient representation of continuous data within quantum systems will play an increasingly important role in next-generation computational approaches for healthcare and life sciences. The validated workflow represents an important step toward enabling increasingly sophisticated quantum-enabled analytical capabilities as quantum computing technologies continue to evolve.
NeuroThera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. The company's shares trade on the TSX Venture Exchange under the symbol NTLX.
For further information, contact Michal Efraty, IR Manager, at +972-3-7617108 or michal@efraty.com. Neither the TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements based on assumptions management considers reasonable, including that internal validation results are indicative of performance at larger scale and on real-world datasets, and that quantum computing hardware of sufficient capability will exist when required. Forward-looking statements are subject to risks and uncertainties, including that quantum computing is an emerging technology and there is no assurance that any quantum advantage will be achieved. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update them except as required by applicable securities laws.
View the original release on NewMediaWire.
